Dr. Stephen E. Gitelman, M.D.
Pediatric Endocrinology (Pediatric Endocrinology Physician)
At a glance
- In the NPI registry since
- 2006
Licensed in California since 1986, according to the Medical Board of California. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Pediatric Endocrinology Physician primary
CA license A42776 (first issued 1986; current) -
Pediatrics Physician
CA license A42776 (first issued 1986; current)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Payments from drug and device companies
In 2025, 4 companies reported 12 payments worth $34,441 in total to this clinician.
| Genzyme Corporation | $18,505 |
|---|---|
| Sanofi US Services Inc. | $6,730 |
| Sanofi-aventis U.S. LLC | $5,907 |
| Eli Lilly and Company | $3,300 |
| Consulting Fee | $26,314 |
|---|---|
| Compensation for services other than consulting (speaking, faculty) | $6,980 |
| Travel and Lodging | $682 |
| Food and Beverage | $465 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Genzyme Corporation Oct 24, 2025 | Consulting Fee | $17,452 |
| Sanofi-aventis U.S. LLC May 27, 2025 | Consulting Fee TZIELD · Endocrine & Metabolic Diseases | $5,562 |
| Sanofi US Services Inc. Nov 5, 2025 | Compensation for services other than consulting (speaking, faculty) TZIELD · Endocrine & Metabolic Diseases | $5,356 |
| Eli Lilly and Company Jul 16, 2025 | Consulting FeeCompany’s descriptionSERVICES TO SUPPORT RESEARCH RELATED ACTIVITIES | $1,925 |
| Eli Lilly and Company Jul 16, 2025 | Consulting FeeCompany’s descriptionSERVICES TO SUPPORT RESEARCH RELATED ACTIVITIES | $1,375 |
| Sanofi US Services Inc. Mar 31, 2025 | Compensation for services other than consulting (speaking, faculty) | $687 |
| Sanofi US Services Inc. Mar 31, 2025 | Compensation for services other than consulting (speaking, faculty) | $687 |
| Genzyme Corporation Oct 24, 2025 | Travel and Lodging travel to Denver, CO · in-kind | $393 |
| Genzyme Corporation Oct 24, 2025 | Travel and Lodging travel to Denver, CO · in-kind | $289 |
| Sanofi-aventis U.S. LLC Nov 5, 2025 | Compensation for services other than consulting (speaking, faculty) in-kind Company’s descriptionIf more than one clinical reprint is received on the same day, the reported transfer of value will reflect the aggregate total. | $250 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 4 industry-funded studies in 2025, from 2 companies. The companies reported $129,286 in research payments for these studies, mostly to the institutions running them.
- Frexalimab in Preservation of Endogenous Insulin Secretion Compared to Placebo in Adults and Adolescents on Top of Insulin Therapy (FABULINUS)
Genzyme Corporation · Active, not recruiting · NCT06111586 - A Multicenter, Multinational Extension of Study PRV-031-001 to Evaluate the Long-Term Safety of Teplizumab (PRV-031), a Humanized, FcR Non-Binding, Anti-CD3 Monoclonal Antibody, in Children and Adolescents With Recent…
Sanofi US Services Inc. - Teplizumab in Pediatric Stage 2 Type 1 Diabetes
Sanofi US Services Inc. · Completed · NCT05757713 - A Real-World Observational Study Characterizing Patients With Type 1 Diabetes Treated with Teplizumab (TEPLI-REAL)
Sanofi US Services Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.